Platform Diagnostics is creating and developing platform technologies for the In-Vitro diagnostics industry.To ensure widespread adoption of the platform across the Point Of Care (POC) sector, we are interested in collaborating with and licensing to other diagnostic companies. More details are available on the Collaboration page.

Company Background

Formed in 2002, Platform Diagnostics is financed by venture capital investment.

We are focused on delivering an affordable, digital rapid immunoassay in response to the demands of the POC market. The integration of a broad range of disciplines has allowed us to develop a new technology - Capillary Agglutination Technology (CAT). CAT provides a platform for digital, rapid, low cost diagnostic tests perfectly suited to the expanding POC market and overcomes the limitations of currently available techniques. Cost, intellectual property, end-user expectations and added distribution chain margins are all factors restricting entry into this market sector.

Our founders bring expertise in clinical serology, microbiology, rapid immunoassay, magnetic particles, impedance, life sciences and gene reporter systems. Together with an impressive pedigree of invention, patent prosecution, problem solving and commercial focus, the company is set to revolutionise the POC diagnostic test market.

More recently, BBI Holdings Plc and Carclo plc have undertaken to invest in Platform Diagnostics with a view to commercialising this innovative technology.